Healthcare software developer Athenahealth is set to be acquired by private equity firm Veritas Capital and hedge fund Elliott Management in a deal worth approximately $5.5 billion in cash, according to a new report from Reuters. The acquisition would price the medical software developer at approximately $135 per share and will be officially announced on […]
Siemens (NYSE:SI), CVS Health (NYSE:CVS) and Athenahealth (NYSE:ATHN) have joined on as backers of Smart Health Innovation Lab, a new Lancaster, Penn.-based medtech accelerator that opened this week. The accelerator was developed collaboratively by Aspire Ventures, Capital BlueCross, Clio Health and Penn Medicine Lancaster General Health, according to a press release. The incubator lab will provide a 12-week […]
Apple (NSDQ:AAPL) is looking to make more waves in healthcare by turning its iPhone into a databank of medical data as it eyes a possible acquisition of Athenahealth, according to 2 CNBC reports. The tech-sector giant has reportedly been in talks with players in the healthcare industry and developers to try and bring clinical data, including […]
(Reuters) — A former Wells Fargo trader yesterday was cleared of insider trading charges brought by the U.S. Securities & Exchange Commission, after a major appellate decision limited authorities’ ability to pursue such cases. Following a trial before the regulator’s in-house court, Administrative Law Judge Jason Patil dismissed the charges against Joseph Ruggieri, who the SEC said […]
MASSDEVICE ON CALL — Legislative leaders from the House and Senate last week looked to put the kaibosh on 1 of the things they dislike most about Obamacare: The Medicare advisory board that’s supposed to help keep healthcare costs down.
House Speaker John Boehner (R-Ohio) and Sen. Mitch McConnell (R-Ky.), the Senate’s minority leader, told President Barack Obama May 9 that they’ll refuse to nominate any candidates for the Independent Payment Advisory Board. Boehner also said the House will vote this week (again, for the 37th time) on repealing Obamacare entirely, The Hill reports.
The Indian government slashed reimbursement rates for drug-eluting stents by more than 61.5%, down to about $460 from roughly $1,200, aiming to give a boost to its domestic stents industry at the expense of the multinational players.
It’s the 2nd rate cut since October 2011, according to the Business Standard. India cut the rate of reimbursement for U.S.-made stents from 65,000 rupees (about $1,200) to 25,000 rupees (~$461), which is now the standard rate for stents regardless of origin, according to the newspaper.
Earlier this week a company director, Frederick Moll, picked up another 5,000 shares at $24.15 each, representing the 1st insider buy on the open market since late last year.
The market for hip and knee implants is stable but mired in a low-growth stage, according to analysts who attended the American Academy of Orthopedic Surgeons conference in San Francisco last week.
Although the abrupt departure of Stryker CEO Steve MacMillan drew the lion’s share of attention at the AAOS event, analysts from Barclays Capital and Leerink Swann agreed that the sector’s outlook calls for low-single-digit growth.
Medsquire LLC slapped 14 companies, including some of corporate America’s biggest names, with a patent infringement lawsuit covering electronic medical records systems.